|
Apr 23
|
Update: Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
European Equities Surge Higher in Wednesday Trading; EC Fines Meta, Apple for DMA Violations
|
|
Apr 23
|
Novartis, Sanofi CEOs Say EU Should Hike Drug Prices to Boost Innovation
|
|
Apr 23
|
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi
|
|
Apr 23
|
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement
|
|
Apr 23
|
European pharma companies push for higher drug prices in EU amid U.S. tariff threats
|
|
Mar 14
|
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
|
|
Feb 24
|
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
|
|
Feb 23
|
Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
|
|
Feb 22
|
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
|
|
Feb 22
|
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
|
|
Feb 21
|
Pharma Stock Roundup: EU Nod to MRK's Welireg, IONS' Q4 Results & More
|
|
Feb 19
|
Sanofi moves closer to selling controlling stake in $17bn-valued Opella
|
|
Feb 19
|
Challenges mount for vaccine makers
|
|
Feb 19
|
Press Release: Sanofi and CD&R sign Opella share purchase agreement
|
|
Feb 18
|
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
|
|
Feb 18
|
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
|
|
Feb 18
|
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
|
|
Feb 7
|
Sanofi increases ownership stake partaking in pharma buyback trend
|
|
Feb 7
|
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
|